TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02022644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
Study: NCT02251132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV high 1
Study: NCT00324324

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
Study: NCT01806753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent midazolam/propofol injection controlled by endoscopist
Description: In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous propofol infusion with opioid administration
Description: In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min.
Study: NCT04047433

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: screening for single nucleotide polymorphism
Description: samples from both arms will be tested for a set of single nucleotide polymorphism
Study: NCT02251132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV high 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV high 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV low
Study: NCT04047433

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: screening for single nucleotide polymorphism
Description: samples from both arms will be tested for a set of single nucleotide polymorphism

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: whole exome sequencing
Description: samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
Study: NCT03310554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 26cm suspended overlength biliary stents
Description: The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30cm suspended overlength biliary stents
Description: The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
Study: NCT02251132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high
Study: NCT03310554

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ordinary plastic biliary stents
Description: The control group will be placed ordinary plastic biliary stents in bile duct in ERCP
Study: NCT00385242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron emission tomography: FDG viability imaging
Description: FDG PET viability imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET imaging
Description: PET viability imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET imaging
Description: PET viability imaging
Study: NCT00535223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Based Exposure Therapy
Description: GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
Study: NCT02022644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
Study: NCT00535223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Present Centered Group Therapy
Description: Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus.
Study: NCT01320462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoking cessation counselling group
Description: The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up

Intervention type: OTHER
Group type: OTHER
Intervention: Control group:
Description: Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
Study: NCT04311424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C Tirzepatide
Description: Administered SC.
Study: NCT03597958

Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
Study: NCT03318354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Olmesartan Medoxomil Tablets 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daiichi Sankyo Inc's Benicar Tablets 40 mg
Study: NCT01114165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of microbial DNA in blood by SeptiFast Test
Description: The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pathogen detection by blood culture
Description: Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
Study: NCT00743327

Intervention type: DRUG
Intervention: Pioglitazone
Description: 45mg capsule, once daily for 1 year
Study: NCT03352323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: RLD
Study: NCT02251132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin
Study: NCT01656590

Intervention type: OTHER
Group type: OTHER
Intervention: High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding
Description: 1. High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age \& gender~2. 500 cc Formula - Nutren Replete with Fiber overnight \[8 hours\] via gastrostomy tube~3. Conditioning Exercise once daily
Study: NCT03106220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: home exercise program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: encourage walking and physical therapy per standard care.
Study: NCT01297140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questioning
Description: Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
Study: NCT03793582

Intervention type: DIAGNOSTIC_TEST
Intervention: ApneaLink Type III portable sleep study
Description: Type III portable sleep study
Study: NCT04291391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: North American-type diet
Description: All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: North American-type diet
Description: All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: North American-type diet
Description: All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: North American-type diet
Description: All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)
Study: NCT01709851

Intervention type: DEVICE
Intervention: Vascular microdialysis using the GMD-system
Description: Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system

Intervention type: DEVICE
Intervention: Vascular and subcutaneous microdialysis using the GMD-system
Description: Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
Study: NCT03282942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training group
Description: Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~* Squatting~* Leg press~* Knee Extension~* Knee Flexion~* Supine Challenge~* High Pull~* Elbow flexion~* Extension of elbows~* Development~* Abdominal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training Group
Description: Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
Study: NCT04506476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C
Description: Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C
Description: Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy.
Study: NCT01865539

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom Foot Orthotic
Description: Custom foot orthotic with custom design pads
Study: NCT01865539

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Orthotic
Description: Leather insert without the custom design pads
Study: NCT04324060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol + rhTPO (recombinant human thrombopoietin injection)
Description: subcutaneous injection, 300U/kg/d×14d every month，stop if the PLT≥100×10e9/L or increased \>50×10e9/L, total course is 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danazol + sodium chloride
Description: Danazol 0.2g tid po+ control (sodium chloride)
Study: NCT00864149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg Tablets, single dose
Description: A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coreg® 12.5 mg Tablets , single dose
Description: B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
Study: NCT03019939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Given PO or IV
Study: NCT01256554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SSRS)
Description: Target dose of 18 or 24 Gy to spine in single session of radiation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
Study: NCT01620710

Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated helical IMRT
Description: hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy

Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated helical IMRT
Description: hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy

Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated helical IMRT
Description: helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)

Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated helical IMRT
Description: helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
Study: NCT02022644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan
Description: The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
Study: NCT01355094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KCI AbThera
Description: The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stampede VAC
Description: The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing.
Study: NCT02251132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled erythromycin
Study: NCT03819608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real iTBS
Description: Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real iTBS
Description: Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: real APT
Description: APT-III is an attention processing training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real APT
Description: APT-III is an attention processing training program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo APT
Description: computerized cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo APT
Description: computerized cognitive training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo iTBS
Description: delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo iTBS
Description: delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
Study: NCT01609335

Intervention type: DRUG
Group type: OTHER
Intervention: F-18 FDG
Description: One time intravenous administration of 17 millicurie (mCi) +/- 10%

Intervention type: DRUG
Group type: OTHER
Intervention: C-11 PiB
Description: One time intravenous administration of 10-20 mCi
Study: NCT00791557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: IV drug given at weeks 1,2,14,22
Study: NCT02238340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release oxycodone
Description: 10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release oxycodone
Description: 10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended- release Oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended- release Oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipirone